Most Recent
A judge has vacated an upcoming trial in shareholder class actions against former Quintis director Frank Wilson and Ernst & Young, after learning judgment in similar ASIC proceedings against Wilson will not be delivered before the class action hearing kicks off.
The man behind the Twitter handle Stock Swami has been ordered to pay $275,000 in damages to Tolga Kumova, after a judge found his tweets defamed the mining investor by accusing him of insider trading, misleading the market, and running a pump and dump scheme.
Lawyers for respondents in defamation litigation have been put on notice for their practice of tossing defences around like grenades in armed combat -- it isn't going to fly any more, warns a judge whose docket is stacked with high profile cases.
The state of Western Australia has been left with a $2 million legal bill for defending a defamation action by billionaire Clive Palmer and advancing cross-claims on behalf of premier Mark McGowan, which a judge blasted as "a futile exercise".
A $1.5 million class action settlement against failed logistics provider GetSwift, which a judge termed a "disaster", has been revised down to $1 million and may face a liquidators' challenge that could see a group members recover nothing.
A law firm has lost its bid to challenge a court order that it join forces with a competing firm in an investor class action against Blue Sky Alternative Investments and auditor EY.
A psychiatrist that sued HarperCollins for defamation over a book on the use of deep sleep therapy at the Chelmsford Private Hospital in the 1970s has lost his bid to disallow the publisher’s claim that any damage he suffered was mitigated by his bad reputation.
The High Court won't hear an appeal by payday loan providers Cigna and BHF seeking to challenge a Full Court judgment that found they can't dodge the obligations contained in the National Credit Code through their lending model.
A contradictor has argued that the High Court must consider the reputation of Botox maker Allergan’s trade marks in a cosmetic company’s challenge to a judgment finding it infringed the marks by marketing its topical creams as Botox alternatives.